- ICH GCP
- Реестр клинических исследований США
- Клиническое испытание NCT03378531
A Study of AEB1102 (Pegzilarginase) in Patients With Arginase 1 Deficiency
An Open-label, Multicentre Study to Evaluate the Long-Term Safety, Tolerability and Efficacy of AEB1102 in Patients With Arginase 1 Deficiency
The purpose of this study is to determine the safety, tolerability, and efficacy of long-term intravenous and subcutaneous administration of pegzilarginase for the treatment of pediatric and adult patients with ARG1-D who complete Study CAEB1102-101A.
Обзор исследования
Статус
Условия
Вмешательство/лечение
Подробное описание
Purpose of this study is to determine the safety, tolerability, and efficacy of long-term intravenous and subcutaneous administration of pegzilarginase for the treatment of pediatric and adult patients with ARG1-D who complete Study CAEB1102-101A.
Тип исследования
Регистрация (Действительный)
Фаза
- Фаза 2
Контакты и местонахождение
Места учебы
-
-
Ontario
-
Toronto, Ontario, Канада, M5G 1X8
- The Hospital for Sick Children
-
-
-
-
-
Porto, Португалия
- Centro Hospitalar S. Joao
-
-
-
-
-
London, Соединенное Королевство
- Great Ormond Street Hospital
-
-
-
-
California
-
Stanford, California, Соединенные Штаты, 94305
- Stanford University School of Medicine
-
-
Florida
-
Gainsville, Florida, Соединенные Штаты, 32610
- University of Florida
-
-
New York
-
New York, New York, Соединенные Штаты, 10029
- Icahn School of Medicine at Mount Sinai
-
-
Texas
-
Dallas, Texas, Соединенные Штаты, 75390
- UTSW
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Описание
Inclusion Criteria:
- Complete treatment in Study CAEB1102-101A without experiencing any clinically significant adverse event or other unmanageable drug toxicity that would preclude continued dosing
- Confirmation by the Investigator and the Sponsor determine that it is acceptable for the patient to continue dosing with AEB1102
- If female and of child-bearing potential, has a negative serum pregnancy test within 7 days before enrollment
- If sexually active (male or female), must be surgically sterile, post-menopausal (female), or must agree to use a physician-approved method of birth control during the study and for a minimum of 30 days after the last study drug administration
- Patient or legal guardian is able and willing to provide written informed consent and where required assent, and to comply with all requirements of study participation (including all study procedures and continuation of prescribed diet without modification), prior to any screening procedures
Exclusion Criteria:
1. Clinically significant concurrent disease, serious intercurrent illness, or other extenuating circumstances
Учебный план
Как устроено исследование?
Детали дизайна
- Основная цель: Уход
- Распределение: Н/Д
- Интервенционная модель: Одногрупповое задание
- Маскировка: Нет (открытая этикетка)
Оружие и интервенции
Группа участников / Армия |
Вмешательство/лечение |
|---|---|
|
Экспериментальный: pegzilarginase (AEB1102)
Each patient may receive pegzilarginase administered IV or SC for up to 4 years. |
modified human arginase I
Другие имена:
|
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Временное ограничение |
|---|---|
|
Number of Participants With Treatment-related Adverse Events
Временное ограничение: From start of study up to 262 weeks
|
From start of study up to 262 weeks
|
|
Number of Participants With Anti-pegzilarginase and Anti-PEG Antibodies
Временное ограничение: From start of study up to 262 weeks
|
From start of study up to 262 weeks
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Plasma Arginine Levels
Временное ограничение: From start of study up to 240 weeks
|
Change in plasma arginine concentrations from study Baseline |
From start of study up to 240 weeks
|
|
Plasma GC Levels (Argininic Acid)
Временное ограничение: From start of study up to 240 weeks
|
Change in plasma argininic acid concentrations from study Baseline |
From start of study up to 240 weeks
|
|
Plasma GC Levels (Guanidinoacetic Acid)
Временное ограничение: From start of study up to 240 weeks
|
Change in plasma guanidinoacetic acid concentrations from study Baseline |
From start of study up to 240 weeks
|
|
Plasma GC Levels (α-keto-δ-guanidinovaleric Acid)
Временное ограничение: From start of study up to 240 weeks
|
Change in plasma α-keto-δ-guanidinovaleric acid concentrations from study Baseline |
From start of study up to 240 weeks
|
|
Plasma GC Levels (α-N-acetylarginine)
Временное ограничение: From start of study up to 240 weeks
|
Change in plasma α-N-acetylarginine concentrations from study Baseline |
From start of study up to 240 weeks
|
|
Six-Minute Walk Test (6MWT)
Временное ограничение: From start of study up to 262 weeks
|
Change in 6MWT distance from study Baseline |
From start of study up to 262 weeks
|
|
Gross Motor Function Measure (GMFM) Part D
Временное ограничение: From start of study up to 262 weeks
|
Change from study Baseline. The GMFM-D evaluates the patient's ability to stand via assessment of 13 activities, each of which is scored on a scale of 0 to 3, with a scale range of 0-39 points. An increase in GMFM-D score indicates improvement in standing. |
From start of study up to 262 weeks
|
|
Gross Motor Function Measure (GMFM) Part E
Временное ограничение: From start of study up to 262 weeks
|
Change from study Baseline. The GMFM-E evaluates a subject's ability to walk, run, and jump via assessment of 24 activities, each of which is scored on a scale of 0 to 3, , with a scale range of 0-72. A higher GMFM-E score indicates greater ability, with increasing scores indicating improvement in walking, running, and jumping. |
From start of study up to 262 weeks
|
|
Modified Ashworth Scale (MAS)
Временное ограничение: From start of study up to 262 weeks
|
Spasticity improvement for lower body muscle groups based on MAS from study Baseline. The MAS is used to measure the resistance to passive movement about a joint due to spasticity using a 6-point scoring scale with possible values of 0, 1, 1+ (scored as 1.5), 2, 3, and 4, where 0 is no increase in muscle tone (no spasticity) and 4 is affected part(s) rigid in flexion or extension (total rigidity). Thus, a decrease in MAS score indicates improvement in spasticity. |
From start of study up to 262 weeks
|
|
Berg Balance Scale (BBS)
Временное ограничение: From start of study up to 262 weeks
|
Change from study Baseline. The BBS, a measure of balance, utilizes a 5-point scoring scale of 0 (indicating the lowest level of function) to 4 (indicating the highest level of function) for 14 tasks, giving a scale range of 0-56, with a higher score representing better balance. |
From start of study up to 262 weeks
|
|
Purdue Pegboard Test (Dominant Hand)
Временное ограничение: From start of study up to 262 weeks
|
Change from study Baseline. The Purdue Pegboard Test evaluates manipulative dexterity and bimanual coordination, measuring performance speed in a fine motor task via gross movements of the arms, hands, and fingers, as well as fine motor extremity dexterity. A higher Purdue Pegboard Test score indicates better dexterity and coordination. Scores were compared to normative data, compiled from healthy individuals, to produce a Z-score (0 being population mean). A positive Z-score indicates the raw score is higher than the mean average; a negative Z-score indicates the raw score is below the mean average. |
From start of study up to 262 weeks
|
|
Purdue Pegboard Test (Non-dominant Hand)
Временное ограничение: From start of study up to 262 weeks
|
Change from study Baseline. The Purdue Pegboard Test evaluates manipulative dexterity and bimanual coordination, measuring performance speed in a fine motor task via gross movements of the arms, hands, and fingers, as well as fine motor extremity dexterity. A higher Purdue Pegboard Test score indicates better dexterity and coordination. Scores were compared to normative data, compiled from healthy individuals, to produce a Z-score (0 being population mean). A positive Z-score indicates the raw score is higher than the mean average; a negative Z-score indicates the raw score is below the mean average. |
From start of study up to 262 weeks
|
|
Number of Participants With Hyperammonemic Episodes
Временное ограничение: From study start up to 262 weeks
|
Hyperammonemic episodes" are defined as either an AE for which an Investigator observed symptoms considered to be consistent with a "hyperammonemic episode", or an AE in a patient meeting all 3 of the following criteria: 1. Confirmed ammonia level ≥100 μM, 2. One or more symptoms related to hyperammonemia, 3. Requiring hospitalization or emergency room management. |
From study start up to 262 weeks
|
|
Number of Participants With Seizures
Временное ограничение: From study start up to 262 weeks
|
From study start up to 262 weeks
|
Соавторы и исследователи
Спонсор
Соавторы
Следователи
- Директор по исследованиям: Mattias Rudebeck, PhD MSc BMedSc, Immedica Pharma AB
Публикации и полезные ссылки
Даты записи исследования
Изучение основных дат
Начало исследования (Действительный)
Первичное завершение (Действительный)
Завершение исследования (Действительный)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Действительный)
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Дополнительные соответствующие термины MeSH
- Заболевания головного мозга
- Заболевания центральной нервной системы
- Заболевания нервной системы
- Метаболизм, врожденные ошибки
- Генетические заболевания, врожденные
- Метаболические заболевания
- Заболевания головного мозга, Метаболические, Врожденные
- Заболевания головного мозга, Метаболические
- Метаболизм аминокислот, врожденные ошибки
- Нарушения цикла мочевины, врожденные
- Врожденные, наследственные и неонатальные заболевания и аномалии
- Пищевые и метаболические заболевания
- Гипераргининемия
Другие идентификационные номера исследования
- CAEB1102-102A
Планирование данных отдельных участников (IPD)
Планируете делиться данными об отдельных участниках (IPD)?
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
продукт, произведенный в США и экспортированный из США.
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .